secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001326732-25-000074
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor Q2 2025 revenue $43.6M, net loss $30.8M; Incyte milestone $25M
---------------------------------------------------------------------

- Revenue $43.6M (up from $23.9M Q2 2024); net loss $30.8M ($0.41/share) vs $67.3M ($1.09) prior year.
- Cash and securities $663.8M (Dec 2024: $706.7M); guidance for year-end $555-585M, runway into 2028.
- Earned $25M regulatory milestone from Incyte for Monjuvi FDA approval in follicular lymphoma.
- Initiated Phase 2b XENITH-UC study of XmAb942 in ulcerative colitis; plans to present XmAb819 data in Q4 2025.
- Appointed Raymond Deshaies, Ph.D., to board of directors; he previously led global research at Amgen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000074/0001326732-25-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000074/xncr-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001326732-25-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer